Literature DB >> 33759935

Lucio's phenomenon, a mutilating manifestation of leprosy.

Eduardo Vinicius Mendes Roncada1, Isabella Andrade Marques2, Marilda Aparecida Milanez Morgado de Abreu1.   

Abstract

Entities:  

Year:  2021        PMID: 33759935      PMCID: PMC8008898          DOI: 10.1590/0037-8682-0874-2020

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


× No keyword cloud information.
A 44-year-old man was referred to our hospital with purple spots on his skin seven days prior. Dermatological examination revealed macules, erythematous violaceous papules, hemorrhagic blisters, and ulcerations with a clean background in the legs, feets, and hands were observed. No comorbidities or use of medications was noted. A similar episode occurred two years ago, in which the fifth left pododactyl was amputated. During hospitalization, he developed necrotic areas in his right toes (Figure 1). Laboratory test results were as follows: anti-cardiolipin IgG, 24.7 (positive: >20 GLP); IgM, 150 (positive: >20 MPL), antinuclear factor positive 1:160; and mixed standard, fine dotted nuclear, homogeneous nucleolar, and spindle-type mitotic patterns were observed. Histopathological examination revealed diffuse histiocytic infiltrate; a foamy appearance; several alcohol-acid-resistant bacilli in Ziehl-Neelsen's stain, sometimes in the wall and inside the vessel; and presence of erythrodiapedesis and eosinophils (vasculitis) (Figure 2). However, the other tests did not change. The diagnosis was lepromatous leprosy, suggesting Lucio’s phenomenon (LF). After starting the specific treatment, there was a significant improvement in the lesions and elimination of necrotic areas in three weeks (Figure 3). The patient was discharged from the hospital and was followed up as an outpatient.
FIGURE 1:

(A) Plantar region of the right foot with ulcerations and areas of necrosis on the toes at the first day of hospitalization. (B) Dorsal region of the right foot with areas of necrosis.

FIGURE 2:

(A) Ziehl-Neelsen stain (40×) in this image; the Hansen’s bacilli are red stained with fuchsin, and they are isolated or bounded together forming the globi (black circles) in the macrophage’s cytoplasm, designated as Virchow’s cells; (B) Ziehl-Neelsen stain (100×). In the upper dermis, the presence of numerous Hansen’s bacilli was observed, isolated (arrow 1) and in clusters (black circle). Another important characteristic such as the presence of Hansen’s bacilli invading the vessel (arrow 2) can be seen; (C) Ziehl-Neelsen stain (400×). The presence of Hansen’s bacilli through the dermis and surrounding the blood vessel, invading the vascular wall (arrow 3) and in the vascular lumen (arrow 4).

FIGURE 3:

(A) Plantar region of the right foot with significant improvement. (B) Dorsal region of the right foot with significant improvement 20 days after starting the specific treatment.

LF is a rare manifestation of lepromatous leprosy , . It is clinically characterized by multiple painful erythematous violaceous macules and hemorrhagic blisters, which evolve into necrotic and ulcerated lesions . Generally, this condition affects the upper and lower extremities. Patients who were diagnosed late can suffer from complications such as sepsis, amputations, and death from blood clotting disorders .
  2 in total

1.  Lucio's phenomenon: another case reported in Brazil.

Authors:  Rodrigo Monteiro; Marilda Aparecida Milanez Morgado de Abreu; Marcelo Guimarães Tiezzi; Eduardo Vinícios Mendes Roncada; Claudia Cardoso Macedo de Oliveira; Luciena Cegatto Martins Ortigosa
Journal:  An Bras Dermatol       Date:  2012 Mar-Apr       Impact factor: 1.896

2.  Lucio's phenomenon. Case study of an exceptional response to treatment exclusively with multibacillary multidrug therapy.

Authors:  Amanda Braga Peixoto; Poliana Santin Portela; Fabiano Roberto Pereira de Carvalho Leal; Arles Martins Brotas; Nilton Carlos dos Santos Rodrigues
Journal:  An Bras Dermatol       Date:  2013 Nov-Dec       Impact factor: 1.896

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.